Breast conserving treatment for breast cancer: dosimetric comparison of different non-invasive techniques for additional boost delivery

Radiation Oncology

Mark De Ridder¹  Guy Storme¹  Dirk Verellen¹  Karina Heuninckx¹  Truus Reynders¹  Hilde Van Parijs¹ 

[1] UZ Brussel, Vrije Universiteit Brussel (VUB), Brussels, Belgium

关键词: Vero;    TomoTherapy;    Intensity modulated radiotherapy (IMRT);    Image guided radiation treatment (IGRT);    Tumor bed boost;    Breast cancer;   

Others  :  814910
DOI  :  10.1186/1748-717X-9-36

 received in 2013-04-22, accepted in 2014-01-09,  发布年份 2014

【 摘 要 】

Background

Today it is unclear which technique for delivery of an additional boost after whole breast radiotherapy for breast conserved patients should be state of the art. We present a dosimetric comparison of different non-invasive treatment techniques for additional boost delivery.

Methods

For 10 different tumor bed localizations, 7 different non-invasive treatment plans were made. Dosimetric comparison of PTV-coverage and dose to organs at risk was performed.

Results

The Vero system achieved an excellent PTV-coverage and at the same time could minimize the dose to the organs at risk with an average near-maximum-dose (D2) to the heart of 0.9 Gy and the average volume of ipsilateral lung receiving 5 Gy (V5) of 1.5%. The TomoTherapy modalities delivered an average D2 to the heart of 0.9 Gy for the rotational and of 2.3 Gy for the static modality and an average V5 to the ipsilateral lung of 7.3% and 2.9% respectively. A rotational technique offers an adequate conformity at the cost of more low dose spread and a larger build-up area. In most cases a 2-field technique showed acceptable PTV-coverage, but a bad conformity. Electrons often delivered a worse PTV-coverage than photons, with the planning requirements achieved only in 2 patients and with an average D2 to the heart of 2.8 Gy and an average V5 to the ipsilateral lung of 5.8%.

Conclusions

We present advices which can be used as guidelines for the selection of the best individualized treatment.

【 授权许可】

   
2014 Van Parijs et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Nielsen HM, Overgaard M, Grau C, Jensen AR, Overgaard J: Study of failure pattern among high-risk breast cancer patients with or without postmastectomy radiotherapy in addition to adjuvant systemic therapy: long-term results from the Danish Breast Cancer Cooperative Group DBCG 82 b and c randomized studies. J Clin Oncol 2006, 24:2268-2275.
• [2]Early Breast Cancer Trialists’ Collaborative Group (EBCTCG): Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10 801 women in 17 randomised trials. Lancet 2011, 378:1707-1716.
• [3]Marie O, Maj-Britt J, Jens O, Hansen PS, Carsten R, Michael A, Claus K, Mogens K, Gadeberg CC, Birgitte Bruun R, Mogens B-T, Mouridsen HT: Postoperative radiotherapy in high-risk postmenopausal breast cancer patients given adjuvant tamoxifen: Danish Breast Cancer Cooperative Group DBCG 82c randomised trial. Lancet 1999, 353:1641-1648.
• [4]Overgaard M, Hansen P, Overgaard J, Rose C, Andersson M, Bach F, Kjaer M, Gadeberg C, Mouridsen H, Jensen M, Zedeler K, for the Danisch Breast Cancer Cooperative Group 82b Trial: Postoperative Radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. NEJM 1997, 337:949-955.
• [5]Early Breast Cancer Trialists' Collaborative Group (EBCTCG): Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005, 366:2087-2106.
• [6]Van de Steene J, Soete G, Storme G: Adjuvant radiotherapy for breast cancer significantly improves overall survival: the missing link. Radiother Oncol 2000, 55:263-272.
• [7]Vinh-Hung V, Verschraegen C: The Breast Conserving Surgery Project: Breast-conserving surgery with or without radiotherapy: pooled-analysis for risks of ipsilateral breast tumor recurrence and mortality. J Natl Cancer Inst 2004, 96:115-121.
• [8]Taylor ME, Haffty BG, Rabinovitch R, Arthur DW, Halberg FE, Strom EA, White JR, Cobleigh MA, Edge SB: ACR appropriateness criteria on postmastectomy radiotherapy expert panel on radiation oncology-breast. Int J Radiat Oncol Biol Phys 2009, 73:997-1002.
• [9]Buchholz TA: Radiation therapy for early-stage breast cancer after breast-conserving surgery. N Engl J Med 2009, 360:63-70.
• [10]Sautter-Bihl M-L, Sauer R: Once More Confirmed: Adjuvant Radiotherapy and Improved Local Control Provide a Significant Survival Benefit for Early Breast Cancer Patients. Strahlenther Onkol 2005, 182:199-201.
• [11]Bartelink H, Horiot JC, Poortmans PM, Struikmans H, Van den Bogaert W, Fourquet A, Jager JJ, Hoogenraad WJ, Oei SB, Warlam-Rodenhuis CC, Pierart M, Collette L: Impact of a higher radiation dose on local control and survival in breast-conserving therapy of early breast cancer: 10-year results of the randomized boost versus no boost EORTC 22881–10882 trial. J Clin Oncol 2007, 25:3259-3265.
• [12]Poortmans P, Bartelink H, Horiot JC, Struikmans H, Van den Bogaert W, Fourquet A, Jager J, Hoogenraad W, Rodrigus P, Warlam-Rodenhuis C, Collette L, Pierart M: EORTC Radiotherapy and Breast Cancer Groups: The influence of the boost technique on local control in breast conserving treatment in the EORTC 'boost versus no boost' randomized trial. Radiother Oncol 2004, 72:25-33.
• [13]Van Parijs H, Miedema G, Vinh-Hung V, Verbanck S, Adriaenssens N, Kerkhove D, Reynders T, Schuermans D, Leysen K, Hanon S, Van Camp G, Vincken W, Storme G, Verellen D, De Ridder M: Short course radiotherapy with simultaneous integrated boost for stage I-II breast cancer, early toxicities of a randomized clinical trial. Radiation Oncology 2012, 7:80-90. BioMed Central Full Text
• [14]Depuydt T, Verellen D, Haas O, Gevaert T, Linthout N, Duchateau M, Tournel K, Reynders T, Leysen K, Hoogeman M, Storme G, De Ridder M: Geometric accuracy of a novel gimbals based radiation therapy tumor tracking system. Radiother Oncol 2011, 98:365-372.
• [15]Paddick I: A simple scoring ratio to index the conformity of radiosurgical treatment plans. J. Neurosurg 2000, 93:219-222.
• [16]Reynders T, Tournel K, De Coninck P, Heymann S, Vinh-Hung V, Van Parijs H, Duchateau M, Linthout N, Gevaert T, Verellen D, Storme G: Dosimetric assessment of static and helical TomoTherapy in the clinical implementation of breast cancer treatments. Radioth Oncol 2009, 93:71-79.
• [17]Grégoire V, Mackie T: State of the art on dose prescription, reporting and recording in intensity-modulated radiation therapy (ICRU report No. 83). Cancer/Radiothérapie 2011, 15:555-559.
• [18]Knöös T, Wieslander E, Cozzi L, Brink C, Fogliata A, Albers D, Nystrom H, Lassen S: Comparison of dose calculation algorithms for treatment planning in external photon beam therapy for clinical situations. Phys Med Biol 2006, 51:5785-5807.
• [19]Lievens Y: Hypofractionated breast radiotherapy: Financial and economic consequences. The Breast 2010, 19:192-197.
• [20]Darby SC, Ewertz M, McGale P, Bennet A, Blom-Goldman U, Bronnum D, Correa C, Cutter D, Gagliardi G, Gigante B, Jensen MB, Nisbet A, Peto R, Rahimi K, Taylor C, Phil D, Hall P: Risk of ischemic heart disease in women after radiotherapy for breast cancer. N Engl J Med 2013, 368:987-998.
• [21]Cao J, Roeske JC, Chmura SJ, Salama JK, Shoushtari AN, Boyer AL, Martel MK: Calculation and prediction of the effect of respiratory motion on whole breast radiation therapy dose distributions. Med Dosim 2009, 34:126-132.
• [22]Sterpin E, Janssens G, Orban De Xivry J, Goossens S, Wanet M, Lee JA, Delor A, Bol V, Vynckier S, Gregoire V, Geets X: Helical tomotherapy for SIB and hypo-fractionated treatments in lung carcinomas: a 4D Monte Carlo treatment planning study. Radiother Oncol 2012, 104:173-180.
• [23]Hardenbergh PH, Munley MT, Bentel GC, Kedem R, Borges-Neto S, Hollis D, Prosnitz L, Marks L: Cardiac perfusion changes in patients treated for breast cancer with radiation therapy and doxorubicin: preliminary results. Int J Radiat Oncol Biol Phys 2001, 49:1023-1028.
• [24]Chung E, Corbett JR, Moran JM, Griffith KA, Marsh RB, Feng M, Jagsi R, Kessler ML, Ficaro EC, Pierce LJ: Is there a dose–response relationship for heart disease with low-dose radiation therapy? Int J Radiat Oncol Biol Phys 2013, 85:959-964.
• [25]Verbanck S, Hanon S, Schuermans D, Van Parijs H, Vinh-Hung V, Miedema G, Verellen D, Storme G, Vanhoeij M, Lamote J, De Ridder M, Vincken W: Small airways function in breast cancer patients before and after radiotherapy. Breast Cancer Res Treat 2012, 135:857-865.